Preprint Case Report Version 1 This version is not peer-reviewed

Classic Hodgkin Lymphoproliferative Diseases Clonally Unrelated to B-Chronic Lymphocytic Leukemia Successfully Treated with Bendamustine Plus Rituximab

Version 1 : Received: 7 August 2018 / Approved: 7 August 2018 / Online: 7 August 2018 (12:02:58 CEST)

A peer-reviewed article of this Preprint also exists.

Rai, S.; Tanaka, H.; Fujimoto, K.; Kumode, T.; Inoue, H.; Taniguchi, Y.; Morita, Y.; Espinoza, J.L.; Tatsumi, Y.; Ashida, T.; Matsuoka, R.; Kikuti, Y.Y.; Nakamura, N.; Matsumura, I. Classic Hodgkin Lymphoproliferative Diseases Clonally Unrelated to B-Chronic Lymphocytic Leukemia Successfully Treated with Bendamustine Plus Rituximab. Cancers 2018, 10, 304. Rai, S.; Tanaka, H.; Fujimoto, K.; Kumode, T.; Inoue, H.; Taniguchi, Y.; Morita, Y.; Espinoza, J.L.; Tatsumi, Y.; Ashida, T.; Matsuoka, R.; Kikuti, Y.Y.; Nakamura, N.; Matsumura, I. Classic Hodgkin Lymphoproliferative Diseases Clonally Unrelated to B-Chronic Lymphocytic Leukemia Successfully Treated with Bendamustine Plus Rituximab. Cancers 2018, 10, 304.

Journal reference: Cancers 2018, 10, 304
DOI: 10.3390/cancers10090304

Abstract

A 62-year-old male was diagnosed with B-CLL and treated with Fludarabine-containing regimen which maintained the disease in partial response. Nine years after diagnosis, a rapidly growing systemic lymphadenopathy was observed, and a biopsy specimen revealed the presence of typical Hodgkin/Reed–Sternberg (HRS) cells, surrounded by T-lymphocytes and CLL cells. Sequencing analysis of the germline CDR3 region of the IGH gene showed that the HRS cells were clonally unrelated to the preexisting CLL cells and the HRS cells were composed of five different clones, leading to the molecular diagnosis of de novo lymphocyte-rich classic Hodgkin LPDs with SLL. Because the initial treatment was neither effective for classic Hodgkin LPDs nor for SLL, Bendamustine, Rituximab (BR) was started and complete remission was achieved, which has continued for more than one year so far. BR may be a good therapeutic option for both entities without causing hematological toxicity.

Subject Areas

Lymphoproliferative diseases, Hodgkin lymphoma, Chronic Lymphocytic Leukemia, clonality, Hodgkin/Reed–Sternberg cell, Bendamustine

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.